Stivarga final NICE recommendation for hepatocellular carcinoma
Bayer’s Stivarga has received a final green light from the National Institute for Health and Care Excellence (NICE) for use by the NHS to treat advanced liver cancer.
Read More
Tag: Child–Pugh grade A liver impairment
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
